FDA Safety Flag
The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.
Not Approved
This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.
No Human Data
No human exposure data has been identified for this substance. All available evidence comes from animal models or in vitro studies. Safety in humans is completely unknown.
Evidence visual
MOTS-c evidence and risk matrix
advanced researcher fit
Evidence
Tier C
Risk
high
Regulatory
not approved
WADA
unknown
FDA
flagged
Route
subcutaneous
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
MOTS-c regulates metabolic homeostasis and improves insulin sensitivity in mouse models. Described as an exercise-induced mitochondrial-encoded peptide. Mouse studies use 0.5 mg/kg/day IP dosing. FDA states it has not identified human exposure data for MOTS-c compounded drug products and flags significant immunogenicity/characterization risks.
Decision path
Where MOTS-c fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether MOTS-c belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Regulates metabolic homeostasis; improves insulin sensitivity and reduces obesity/insulin resistance in mouse models.
subcutaneous
Mouse: 0.5 mg/kg/day intraperitoneal. No established human dosing.
Preclinical: improved insulin sensitivity, metabolic regulation, exercise performance in mice.
Metabolic endpoints assessed over days to weeks in mice; exercise performance improvements after ~10 days.
No human data.
FDA: no identified human exposure data; significant immunogenicity/characterization risks.
Unknown.
Cost at a glance
Typical cycle cost
€33.02
Estimated monthly
€33.02
Protocol style
Insufficient evidence
Insufficient evidence
Estimate confidence
High confidence
Assumes roughly 6 mg–12 mg per cycle, using 1 tracked affiliated listing.
Human cycle evidence is weak, so this stays a monthly planning approximation only.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for MOTS-c.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.